117 related articles for article (PubMed ID: 38785683)
21. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.
Struebing A; McKibbon C; Ruan H; Mackay E; Dennis N; Velummailum R; He P; Tanaka Y; Xiong Y; Springford A; Rosenlund M
J Comp Eff Res; 2024 May; 13(5):e230175. PubMed ID: 38573331
[No Abstract] [Full Text] [Related]
22. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
[TBL] [Abstract][Full Text] [Related]
23. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
25. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
28. Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
Wang X; Adamson BJ; Briggs A; Tan K; Bargo D; Ghosh S; Baxi S; Ramsey S
Value Health; 2022 Feb; 25(2):230-237. PubMed ID: 35094796
[TBL] [Abstract][Full Text] [Related]
29. Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E; Hulo P; Guardiolle V; Bodot L; Rabeau A; Porte M; Hiret S; Demontrond P; Curcio H; Boudoussier A; Veillon R; Mayenga M; Dumenil C; Chatellier T; Gourraud PA; Mazieres J; Bennouna J
Cancer Immunol Immunother; 2023 Jun; 72(6):1881-1890. PubMed ID: 36690799
[TBL] [Abstract][Full Text] [Related]
30. Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot.
Lasiter L; Tymejczyk O; Garrett-Mayer E; Baxi S; Belli AJ; Boyd M; Christian JB; Cohen AB; Espirito JL; Hansen E; Sweetnam C; Robert NJ; Small M; Stewart MD; Izano MA; Wagner J; Natanzon Y; Rivera DR; Allen J
Clin Pharmacol Ther; 2022 Feb; 111(2):444-454. PubMed ID: 34655228
[TBL] [Abstract][Full Text] [Related]
31. Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials.
Carrigan G; Whipple S; Capra WB; Taylor MD; Brown JS; Lu M; Arnieri B; Copping R; Rothman KJ
Clin Pharmacol Ther; 2020 Feb; 107(2):369-377. PubMed ID: 31350853
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
[TBL] [Abstract][Full Text] [Related]
33. Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors.
Gaitonde P; Chirikov V; Kelkar S; Liljas B
Cancer Manag Res; 2022; 14():3421-3435. PubMed ID: 36514307
[TBL] [Abstract][Full Text] [Related]
34. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.
Trovo M; Relevant A; Polesel J; Muraro E; Barresi L; Drigo A; Baresic T; Bearz A; Fanetti G; Del Conte A; Matrone F; Reverberi C; Furlan C; Zuccon U; Fontana P; Franchin G; Minatel E
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1368-1376. PubMed ID: 33259933
[TBL] [Abstract][Full Text] [Related]
35. Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma.
Signorovitch J; Moshyk A; Zhao J; Le TK; Burns L; Gooden K; Hamilton M
Future Oncol; 2022 Apr; 18(11):1321-1331. PubMed ID: 35048743
[TBL] [Abstract][Full Text] [Related]
36. Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer.
Børø S; Thoresen S; Boge Brant S; Helland Å
Acta Oncol; 2023 Dec; 62(12):1642-1648. PubMed ID: 37801361
[TBL] [Abstract][Full Text] [Related]
37. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
38. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhang K; Ma X; Gao H; Wang H; Qin H; Yang S; Liu X
Cancer Manag Res; 2020; 12():3409-3417. PubMed ID: 32494205
[TBL] [Abstract][Full Text] [Related]
40. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
Lakdawalla DN; Shafrin J; Hou N; Peneva D; Vine S; Park J; Zhang J; Brookmeyer R; Figlin RA
Value Health; 2017; 20(7):866-875. PubMed ID: 28712615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
